Ventyx Biosciences (VTYX) Expected to Announce Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.13. On average, analysts expect Ventyx Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Stock Performance

NASDAQ:VTYX opened at $1.38 on Tuesday. The firm’s fifty day moving average is $1.24 and its two-hundred day moving average is $1.82. The firm has a market cap of $98.20 million, a price-to-earnings ratio of -0.58 and a beta of 0.73. Ventyx Biosciences has a one year low of $0.78 and a one year high of $5.66.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.